Breaking News Instant updates and real-time market news.

LXRX

Lexicon

$12.81

0.44 (3.56%)

, IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37

Lexicon announces European Commission approves Xermelo

Lexicon Pharmaceuticals (LXRX) announced that the European Commission has approved Xermelo 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults inadequately controlled by SSA therapy. This approval allows for the marketing of Xermelo by Lexicon's collaborator, Ipsen (IPSEY), in the above indication in all 28 member states of the European Union, Norway and Iceland, the company stated.

LXRX

Lexicon

$12.81

0.44 (3.56%)

IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

  • 25

    Sep

LXRX Lexicon
$12.81

0.44 (3.56%)

03/01/17
WEDB
03/01/17
NO CHANGE
WEDB
Lexicon price target raised to $38 from $33 at Wedbush
Wedbush analyst Liana Moussatos increased her price target on Lexicon after the FDA approved Lexicon's lead drug, Zermelo, for carcinoid syndrome. The analyst thinks that the company has several additional upcoming positive potential catalysts. She keeps an Outperform rating on the stock.
03/07/17
SBSH
03/07/17
NO CHANGE
Target $28
SBSH
Buy
Lexicon price target raised to $28 from $24 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Lexicon Pharmaceuticals to $28 saying the company's potential in diabetes remains underappreciated. Management's commentary on sotagliflozin should re-assure investors who remain unconvinced about the T1D thesis, Nochomovitz tells investors in a post-earnings research note. He keeps a Buy rating on Lexicon.
09/13/17
JPMS
09/13/17
NO CHANGE
JPMS
Neutral
Editorial published with Lexicon data reads cautiously, says JPMorgan
JPMorgan analyst Jessica Fye noted that full results for Lexicon Pharmaceuticals' Phase 3 inTandem3 study were released in the New England Journal of Medicine, accompanied by an editorial that reads cautiously on associated diabetic ketoacidosis. The comments from the editorial give her further pause on overall DKA risk and she thinks the relative risk in pumps patients may be at a threshold where physicians and the FDA could be cautious, she tells investors. Fye keeps a Neutral rating on Lexicon shares, which have fallen by more than 9% following the publication.
09/15/17
SBSH
09/15/17
NO CHANGE
Target $28
SBSH
Buy
Lexicon sold off on increased competition concerns, says Citi
Citi analyst Yigal Nochomovitz attributes the 10% selloff yesterday in shares of Lexicon Pharmaceuticals to increased competition after the 24-week results from the Depict1 trial for dapagliflozin in type 1 diabetes were presented. The data are broadly in line with what we've seen from sotagliflozin, suggesting a similar efficacy and safety profile between the two drugs, Nochomovitz tells investors in a research note. He reminds investors that he always expected competition in the adjunctive type 1 diabetes space, and currently models 35% peak share for sotagliflozin, which he thinks leaves "plenty of room for another SGLT inhibitor." The analyst has a Buy rating on Lexicon with a $35 price target.
IPSEY Ipsen
$33.04

-0.36 (-1.08%)

09/19/17
SOCG
09/19/17
UPGRADE
SOCG
Buy
Ipsen upgraded to Buy from Hold at Societe Generale
Societe Generale analyst Delphine Le Louet upgraded Ipsen to Buy with a price target of EUR 126.

TODAY'S FREE FLY STORIES

PERY

Perry Ellis

$27.92

0.31 (1.12%)

05:29
06/18/18
06/18
05:29
06/18/18
05:29
Hot Stocks
Perry Ellis enters into $437M 'going private' deal led by George Feldenkreis »

Perry Ellis announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$9.95

0.5 (5.29%)

05:27
06/18/18
06/18
05:27
06/18/18
05:27
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$9.95

0.5 (5.29%)

05:27
06/18/18
06/18
05:27
06/18/18
05:27
Hot Stocks
Cytokinetics announces data from reldesemtiv Phase 2 clinical study »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBSV

ObsEva

$14.53

-0.72 (-4.72%)

05:26
06/18/18
06/18
05:26
06/18/18
05:26
Conference/Events
ObsEva to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

MDT

Medtronic

$86.78

0.2 (0.23%)

, ISRG

Intuitive Surgical

$490.49

-5.17 (-1.04%)

05:25
06/18/18
06/18
05:25
06/18/18
05:25
Recommendations
Medtronic, Intuitive Surgical analyst commentary  »

Piper continues to…

MDT

Medtronic

$86.78

0.2 (0.23%)

ISRG

Intuitive Surgical

$490.49

-5.17 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

JD

JD.com

$43.63

-0.12 (-0.27%)

, GOOG

Alphabet

$1,151.95

-0.05 (-0.00%)

05:22
06/18/18
06/18
05:22
06/18/18
05:22
Hot Stocks
Google to invest $550M cash in JD.com as part of strategic partnership »

JD.com (JD) and Google…

JD

JD.com

$43.63

-0.12 (-0.27%)

GOOG

Alphabet

$1,151.95

-0.05 (-0.00%)

GOOGL

Alphabet Class A

$1,159.03

-1.08 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Oct

NVS

Novartis

$75.80

-0.19 (-0.25%)

05:20
06/18/18
06/18
05:20
06/18/18
05:20
Hot Stocks
Alcon AcrySof IQ PanOptix trifocal IOL shows superior performance in trial »

Alcon, the global leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYCEY

Rolls-Royce

$0.00

(0.00%)

05:20
06/18/18
06/18
05:20
06/18/18
05:20
Upgrade
Rolls-Royce rating change  »

Rolls-Royce upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASBFY

Associated British Foods

$0.00

(0.00%)

05:18
06/18/18
06/18
05:18
06/18/18
05:18
Upgrade
Associated British Foods rating change  »

Associated British Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACGL

Arch Capital

$80.43

-0.69 (-0.85%)

05:16
06/18/18
06/18
05:16
06/18/18
05:16
Initiation
Arch Capital initiated  »

Arch Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNR

RenaissanceRe

$123.82

-0.33 (-0.27%)

05:15
06/18/18
06/18
05:15
06/18/18
05:15
Initiation
RenaissanceRe initiated  »

RenaissanceRe initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRB

W. R. Berkley

$75.33

0.06 (0.08%)

05:14
06/18/18
06/18
05:14
06/18/18
05:14
Initiation
W. R. Berkley initiated  »

W. R. Berkley initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RE

Everest Re

$226.37

0.38 (0.17%)

05:13
06/18/18
06/18
05:13
06/18/18
05:13
Initiation
Everest Re initiated  »

Everest Re initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$65.82

-0.17 (-0.26%)

05:13
06/18/18
06/18
05:13
06/18/18
05:13
Initiation
Arthur J. Gallagher initiated  »

Arthur J. Gallagher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$18.28

-0.52 (-2.77%)

05:12
06/18/18
06/18
05:12
06/18/18
05:12
Initiation
Kiniksa initiated  »

Kiniksa initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

GSKY

GreenSky

$24.27

-0.18 (-0.74%)

05:11
06/18/18
06/18
05:11
06/18/18
05:11
Initiation
GreenSky initiated  »

GreenSky initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

, XPO

XPO Logistics

$113.89

2.225 (1.99%)

05:11
06/18/18
06/18
05:11
06/18/18
05:11
Hot Stocks
Nestle, XPO Logistics co-creating 638,000-square-foot distribution center in UK »

Nestle (NSRGY) and XPO…

NSRGY

Nestle

$0.00

(0.00%)

XPO

XPO Logistics

$113.89

2.225 (1.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPN

Global Payments

$117.51

-0.24 (-0.20%)

05:09
06/18/18
06/18
05:09
06/18/18
05:09
Downgrade
Global Payments rating change  »

Global Payments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVOP

EVO Payments

$22.98

0.95 (4.31%)

05:05
06/18/18
06/18
05:05
06/18/18
05:05
Initiation
EVO Payments initiated  »

EVO Payments initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$130.91

0.81 (0.62%)

05:04
06/18/18
06/18
05:04
06/18/18
05:04
Downgrade
Chubb rating change  »

Chubb downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$60.17

-0.585 (-0.96%)

05:02
06/18/18
06/18
05:02
06/18/18
05:02
Downgrade
Leidos rating change  »

Leidos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDFN

Redfin

$24.00

-0.64 (-2.60%)

, ZG

Zillow

$65.24

0.45 (0.69%)

05:00
06/18/18
06/18
05:00
06/18/18
05:00
Downgrade
Redfin, Zillow rating change  »

Redfin downgraded to Sell…

RDFN

Redfin

$24.00

-0.64 (-2.60%)

ZG

Zillow

$65.24

0.45 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZG

Zillow

$65.24

0.45 (0.69%)

04:58
06/18/18
06/18
04:58
06/18/18
04:58
Downgrade
Zillow rating change  »

Zillow downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRG

Evergy

$52.75

0.8 (1.54%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Evergy management to meet with Wolfe Research »

Wolfe Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

MDT

Medtronic

$86.78

0.2 (0.23%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Medtronic management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.